BMY vs CODX · P/E 17, rev $48.19B vs rev $3.9M
Bristol-Myers Squibb Company (BMY) versus Co-Diagnostics, Inc. Common Stock (CODX) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Latest reported BMY revenue for 2025-12-31 was $48.19B. Net income was $7.05B. Revenue was down 0.2% from 2024-12-31 to 2025-12-31. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. CODX currently screens at market cap $31.4M.
Not investment advice. Open the BMY and CODX stock pages for the full models.
Not investment advice.